Leading Companies in the India Diabetes Market, Supported by High Prevalence of Diabetes Cases

The India diabetes market size was valued at INR 316 billion in 2023, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16% during the forecast period of 2024-2032, with the values likely to rise from INR 366.56 billion in 2024 to INR 1201.74 billion by 2032. As per the analysis by Expert Market Research, the market is expected to be driven by the developing healthcare infrastructure.

Diabetes arises when blood glucose, also termed blood sugar, reaches too high a point. The body uses glucose, which is also its primary source of energy. Due to diabetes, either the body does not produce enough insulin hormone, or it doesn't use it correctly. After that, it stays in the blood and does not enter cells. Diabetes increases the risk of damaging many body parts like kidney, nerve, heart, among others.

India  is often referred to as the "Diabetes Capital of the World," with 17% of people suffering with diabetes. India diabetes market share is increasing as diabetes is predominantly a lifestyle disease that is dangerously developing in India in all age categories, with a rate that has increased above 10% among younger people.

Digitalized  diabetes care is driving the India diabetes market growth. In India, many innovative and evolving technologies are being considered to reduce the occurrence of diabetes among people. There are several therapeutic advances in endocrinology and metabolism in the market, intended to cater the diverse needs of patients.

Individuals are being driven to act quickly to manage or cure diabetes due to increased understanding of the disease's symptoms and side effects. Nowadays, people know that early detection of diabetes and appropriate treatment methods can greatly postpone the development and progression of its consequences. About 25 million people in India are prediabetics, or at a higher risk of acquiring diabetes in the near future, and an estimated 77 million adults over the age of 18 have type 2 diabetes. Furthermore, the widespread accessibility of blood glucose monitors for monitoring blood sugar levels along with the rising incidence of obesity among working-age individuals is boosting the India diabetes market expansion.

In  2024, Sanofi India Limited announced a new diabetes medication called Soliqua. The medicine was approved by Central Drugs Standard Control Organization (CDSCO) in 2023. It is aimed to treat adults with obesity and type 2 diabetes mellitus. Soliqua work as a medication to improve glycemic control as an addition to diet and exercise, in those whose blood sugar control is inadequate with oral or injectable medicines.

Top 10 Diabetes Companies in India:

Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.  is one of the leading specialty generic pharmaceutical companies. It generated around global revenues of USD 5.4 billion. There are around 43 manufacturing facilities which supply high-grade, affordable medicines, which are trusted by healthcare professionals and patients. They are recognized for their extensive production and promotion of different pharmaceutical formulations. A wide array of chronic and acute care solutions is encompassed in their product range which showcases the commitment to technological advancement. They have also specialized in over-the-counter medications and active pharmaceutical ingredients, among others.

Biocon Limited

Biocon Limited , is one of India's largest biopharmaceutical companies which is fully integrated and innovation led. It is also emerging as a global company in over 120 countries. They are driving global healthcare through innovative and affordable biopharmaceuticals. They have also found access to therapies that are advanced for chronic diseases where there are high treatment costs. Biocon has built biggest and distinct spanning insulins, monoclonal antibodies that are helpful in treating chronic diseases like diabetes, cancer, and autoimmune disorders.

Dr. Reddy's Laboratories Ltd.

Dr. Reddy’s Laboratories Ltd.  is one of the global pharmaceutical companies. They are known for providing affordable and advanced medicines. They offer a diverse portfolio which include APIs, biosimilars, branded generics, OTC. The company is focused on therapeutic areas like diabetology, cardiovascular, pain management and others.  As a firm with expertise in deep research that has generated multiple industry firsts, they keep thinking ahead and making investments in companies that will shape the future.

Novo Nordisk India Pvt. Ltd

Novo  Nordisk is a leading global healthcare company dedicated for providing solutions to the people with serious chronic illnesses. They are leading in diabetes care, by working every day and innovating. The company has a dominant force in both diabetes care and hemophilia management and are working towards individual development. Novo Nordisk insulins have been in India for many decades.

Abbott  India Limited

Abbott is known for its commitment for enhancing health in India through a variety of nutritional products, trademarked generic drugs, and devices for diabetes. Abbott India Limited play an important role within Abbott's worldwide network, which offers dependable and top-notch pharmaceuticals across different sectors like women's health, primary care, and more. They customize products and clinical solutions in a way that it meets local needs, ensuring high-quality, cost-efficient production and adherence to international quality standards.

Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Limited is driven by research and provides branded, generic, and over the counter (OTC) drugs. Their primary focus is on respiratory, dermatological, and oncology therapies. They operate in more than 80 countries and has four R&D centers in addition to 10 top-notch manufacturing facilities dispersed over five continents. Glenmark Pharmaceuticals and US subsidiary Ichnos Sciences also formed a partnership called Ichnos Glenmark Innovation for developing innovative cancer treatments using advanced technology and their combined experience.

Lupin Limited

Lupin   is a multinational pharmaceutical firm which provides active pharmaceutical ingredients (APIs), and branded and generic formulations, among others. Lupin is a prominent participant in the US, India, and Japan, along with other countries in Asia Pacific, EMEA, and LATAM. It is also leading in the cephalosporin and anti-TB markets. They have also received success in therapeutic areas like women's health, diabetic, respiratory, gastrointestinal, and cardiovascular health which is powered by their dedication to innovation and patient-centricity.

Torrent Pharmaceuticals Ltd.

Torrent Pharma , is one of the top pharmaceutical firms which is part of the Torrent Group. They are leading in the therapeutic segments of cardiovascular, central nervous system, women's healthcare, vitamins, minerals, and cosmo-dermatology. They also introduced the concept of niche marketing in India. The company is also providing their expertise in the oncology, diabetology, and anti-infective categories.

Sanofi India Limited

Sanofi  India Limited is one of the leadings healthcare firm across the world. In India, they operate two production facilities in Goa and Hyderabad. These locations are producing goods that meet strict worldwide quality standards and have regulatory agency approval. They manufacture different type of dose forms like tablets, hard and soft capsules, eye/ear drops, ampoules, among others.

Cadila Healthcare Limited

Cadila  Healthcare Limited is one of the biggest pharmaceutical businesses in India. They are known for creating and manufacturing reasonably priced medications for patients worldwide. They use cutting-edge drug discovery procedures which guarantees health and welfare of people. They have increased their focus on innovation and R&D which have led to medical miracles. Cadila is widely known for their treatment of diabetes due to the accessibility of insulin and oral hypoglycemic medications which includes gliclazide, glimepiride, and others.